{
  "symbol": "GILD",
  "year": 2023,
  "Period": "Y2023",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.165,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.203
  },
  "top_positive": [
    {
      "sent": "2022 Equity Incentive Plan (13) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (14) 10.5* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (15) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (16) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (17) 10.8* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) (18) 10.9* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (19) 10.10* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants commencing in 202 2 ) (20) 10.11* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012) (21) 10.12* Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013) (21) 10.13* Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013) (22) 10.14* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018) (14) 10.15* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (23) 10.16* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2020 and 2021 ) (19) 10.17* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants commencing in 2022) (14) 10.18* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019) (16) 10.19* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (17) 10.20* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021) (18) 10.21* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2022) (14) 10.22* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019) (16) 10.23* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (17) 10.24* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021) (18) 10.25",
      "score": 0.9995
    },
    {
      "sent": "The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting: December 31, 2022 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 59 Other current liabilities $ 26 Foreign currency exchange contracts Other long-term assets 1 Other\u00a0long-term\u00a0obligations 9 Total derivatives designated as hedges 59 35 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 7 Total derivatives not designated as hedges 1 7 Total derivatives presented gross on the Consolidated Balance Sheets $ 60 $ 42 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments ( 36 ) ( 36 ) Cash collateral received / pledged \u2014 \u2014 Net amount (legal offset) $ 25 $ 7 66 December 31, 2021 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 75 Other current liabilities $ 4 Foreign currency exchange contracts Other long-term assets 5 Other\u00a0long-term\u00a0obligations 1 Total derivatives designated as hedges 80 5 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets \u2014 Other current liabilities \u2014 Total derivatives not designated as hedges \u2014 \u2014 Total derivatives presented gross on the Consolidated Balance Sheets $ 80 $ 5 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments ( 4 ) ( 4 ) Cash collateral received / pledged \u2014 \u2014 Net amount (legal offset) $ 76 $ 1 The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements: Year Ended December 31, (in millions) 2022 2021 2020 Derivatives designated as hedges: Gain (loss) recognized in Accumulated other comprehensive income $ 150 $ 147 $ ( 118 ) Gain (loss) reclassified from Accumulated other comprehensive income to Product sal\nithin one year $ 1,057 $ 1,048 After one year through five years 1,260 1,236 After five years through ten years 3 3 After ten years 6 6 Total $ 2,325 $ 2,293 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Consolidated Balance Sheets: (in millions) December 31, 2022 December 31, 2021 Cash and cash equivalents $ 3,831 $ 3,661 Prepaid and other current assets (1) 473 885 Other long-term assets (1) 943 1,197 Total $ 5,248 $ 5,743 ________________________________ (1) Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments.",
      "score": 0.9928
    },
    {
      "sent": "Securities Authorized For Issuance Under Equity Compensation Plans The following table provides certain information with respect to our equity compensation plans in effect as of December\u00a031, 2022: (in millions, except per share amounts) Number of Common Shares to be Issued Upon Exercise of Outstanding Options and Rights (1) Weighted-average Exercise Price of Outstanding Options and Rights (1) Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) Plan Category (a) (b) (c) Equity compensation plans approved by security holders: 2022 Equity Incentive Plan 39.1 $ 67.69 100.5 Employee Stock Purchase Plan (2) 3.1 Total equity compensation plans approved by security holders 39.1 $ 67.69 103.7 Equity compensation plans not approved by security holders \u2014 $ \u2014 \u2014 Total 39.1 $ 67.69 103.7 ______________________________________________________ (1) Includes 25\u00a0million restricted stock units, performance share units and phantom shares.",
      "score": 0.9904
    }
  ],
  "top_negative": [
    {
      "sent": "Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy is being evaluated as (i) a second- or third-line treatment for non-small cell lung cancer (\u201cNSCLC\u201d); (ii) a first-line treatment for PD-L1 negative metastatic triple-negative breast cancer (\u201cTNBC\u201d); and (iii) a second-line treatment for metastatic urothelial cancer.",
      "score": -0.9578
    },
    {
      "sent": "Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy is being evaluated as (i) a second- or third-line treatment for non-small cell lung cancer (\u201cNSCLC\u201d); (ii) a first-line treatment for PD-L1 negative metastatic triple-negative breast cancer (\u201cTNBC\u201d); and (iii) a second-line treatment for metastatic urothelial cancer.",
      "score": -0.9578
    },
    {
      "sent": "Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy is being evaluated as (i) a second- or third-line treatment for non-small cell lung cancer (\u201cNSCLC\u201d); (ii) a first-line treatment for PD-L1 negative metastatic triple-negative breast cancer (\u201cTNBC\u201d); and (iii) a second-line treatment for metastatic urothelial cancer.",
      "score": -0.9578
    }
  ],
  "forward_snippets": [
    "We intend to continue committing significant resources to internal R&D opportunities and external business development activity to drive innovation and growth of our business.",
    "The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties.",
    "Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline.",
    "We expect to expend significant time and resources on our R&D activities without any assurance that we will recoup our investments or that our efforts will be commercially successful.",
    "In 2022, we continued to invest in and advance our R&D pipeline across our therapeutic areas."
  ],
  "curated_text": "Symbol: GILD. Year: 2023. Period: Y2023. ReportType: K10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: 2022 Equity Incentive Plan (13) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (14) 10.5* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (15) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (16) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (17) 10.8* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) (18) 10.9* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (19) 10.10* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants commencing in 202 2 ) (20) 10.11* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012) (21) 10.12* Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013) (21) 10.13* Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013) (22) 10.14* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018) (14) 10.15* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (23) 10.16* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2020 and 2021 ) (19) 10.17* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants commencing in 2022) (14) 10.18* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019) (16) 10.19* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (17) 10.20* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021) (18) 10.21* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2022) (14) 10.22* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019) (16) 10.23* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (17) 10.24* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021) (18) 10.25 The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting: December 31, 2022 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 59 Other current liabilities $ 26 Foreign currency exchange contracts Other long-term assets 1 Other\u00a0long-term\u00a0obligations 9 Total derivatives designated as hedges 59 35 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 7 Total derivatives not designated as hedges 1 7 Total derivatives presented gross on the Consolidated Balance Sheets $ 60 $ 42 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments ( 36 ) ( 36 ) Cash collateral received / pledged \u2014 \u2014 Net amount (legal offset) $ 25 $ 7 66 December 31, 2021 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 75 Other current liabilities $ 4 Foreign currency exchange contracts Other long-term assets 5 Other\u00a0long-term\u00a0obligations 1 Total derivatives designated as hedges 80 5 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets \u2014 Other current liabilities \u2014 Total derivatives not designated as hedges \u2014 \u2014 Total derivatives presented gross on the Consolidated Balance Sheets $ 80 $ 5 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments ( 4 ) ( 4 ) Cash collateral received / pledged \u2014 \u2014 Net amount (legal offset) $ 76 $ 1 The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements: Year Ended December 31, (in millions) 2022 2021 2020 Derivatives designated as hedges: Gain (loss) recognized in Accumulated other comprehensive income $ 150 $ 147 $ ( 118 ) Gain (loss) reclassified from Accumulated other comprehensive income to Product sal\nithin one year $ 1,057 $ 1,048 After one year through five years 1,260 1,236 After five years through ten years 3 3 After ten years 6 6 Total $ 2,325 $ 2,293 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Consolidated Balance Sheets: (in millions) December 31, 2022 December 31, 2021 Cash and cash equivalents $ 3,831 $ 3,661 Prepaid and other current assets (1) 473 885 Other long-term assets (1) 943 1,197 Total $ 5,248 $ 5,743 ________________________________ (1) Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Securities Authorized For Issuance Under Equity Compensation Plans The following table provides certain information with respect to our equity compensation plans in effect as of December\u00a031, 2022: (in millions, except per share amounts) Number of Common Shares to be Issued Upon Exercise of Outstanding Options and Rights (1) Weighted-average Exercise Price of Outstanding Options and Rights (1) Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) Plan Category (a) (b) (c) Equity compensation plans approved by security holders: 2022 Equity Incentive Plan 39.1 $ 67.69 100.5 Employee Stock Purchase Plan (2) 3.1 Total equity compensation plans approved by security holders 39.1 $ 67.69 103.7 Equity compensation plans not approved by security holders \u2014 $ \u2014 \u2014 Total 39.1 $ 67.69 103.7 ______________________________________________________ (1) Includes 25\u00a0million restricted stock units, performance share units and phantom shares. Top negative sentences: Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy is being evaluated as (i) a second- or third-line treatment for non-small cell lung cancer (\u201cNSCLC\u201d); (ii) a first-line treatment for PD-L1 negative metastatic triple-negative breast cancer (\u201cTNBC\u201d); and (iii) a second-line treatment for metastatic urothelial cancer. Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy is being evaluated as (i) a second- or third-line treatment for non-small cell lung cancer (\u201cNSCLC\u201d); (ii) a first-line treatment for PD-L1 negative metastatic triple-negative breast cancer (\u201cTNBC\u201d); and (iii) a second-line treatment for metastatic urothelial cancer. Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy is being evaluated as (i) a second- or third-line treatment for non-small cell lung cancer (\u201cNSCLC\u201d); (ii) a first-line treatment for PD-L1 negative metastatic triple-negative breast cancer (\u201cTNBC\u201d); and (iii) a second-line treatment for metastatic urothelial cancer. Forward-looking snippets: We intend to continue committing significant resources to internal R&D opportunities and external business development activity to drive innovation and growth of our business. The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. We expect to expend significant time and resources on our R&D activities without any assurance that we will recoup our investments or that our efforts will be commercially successful. In 2022, we continued to invest in and advance our R&D pipeline across our therapeutic areas."
}